

NCT ID	NCT03313778
Title	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
Phase	Phase 1
Date Added	2017-10-18
Location	Arizona, United States California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Australia Japan United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	mRNA-4157, Pembrolizumab, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT03310008
Title	Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
Phase	Phase 1
Date Added	2017-10-16
Location	Belgium
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	NKR-2 cells
Tags	MSS/ MMRp
NCT ID	NCT03297606
Title	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase	Phase 2
Date Added	2017-09-29
Location	Canada
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03296137
Title	Adoptive Cell Therapy Across Cancer Diagnoses
Phase	Phase 1/Phase 2
Date Added	2017-09-28
Location	Denmark

Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03290937
Title	Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2017-09-25
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, Irinotecan Hydrochloride, Utomilumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03289962
Title	A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase	Phase 1
Date Added	2017-09-21
Location	Arizona, United States California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States Belgium Canada Germany Netherlands Spain Sweden United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, Autogene cevumeran, Tecentriq
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03280511
Title	Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Phase	Phase 2
Date Added	2017-09-12
Location	Denmark
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	PIPAC

Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03239145
Title	Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase	Phase 1
Date Added	2017-08-03
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Trebananib
Tags	MSS/ MMRp
NCT ID	NCT03223779
Title	Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Phase	Phase 1
Date Added	2017-07-21
Location	Massachusetts, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03217747
Title	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
Phase	Phase 1, Phase 2
Date Added	2017-07-14
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio
Tags	MSS/ MMRp